Patients Say Genzyme Mischaracterizes Diluted-Drug Claims
Patients with a life-threatening genetic disorder pushed the First Circuit on Tuesday to revive their putative class action claiming Sanofi subsidiary Genzyme Corp. watered down doses of Fabrazyme and caused their...To view the full article, register now.
Already a subscriber? Click here to view full article